BRCA

DCGI approved Astra Zeneca’s Lynparza as a monotherapy for adjuvant treatment of patients with high-risk early breast cancer

·         Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer ·         New Data from OlympiA Phase…

2 years ago

A New Approach to Tailoring Cancer Therapy: Tapping into Signaling Activities in Cancer Cells

Matching drugs to tumors may lead to personalized treatment and new therapies New Delhi, July 21, 2020; Choosing the right drug for…

4 years ago